Ruzasvir

Mayo Clinic Arizona's removal of Clostridioides difficile from gastrointestinal pathogen panels reduced unnecessary treatments and improved diagnostic stewardship. A Salmonella outbreak linked to cucumbers sickened 68 across 19 US states, prompting a recall. The Equity in Antimicrobial Stewardship Efforts (EASE) framework aims to address disparities in antimicrobial prescribing. Atea Pharmaceuticals' hepatitis C therapy achieved a 98% sustained virologic response in a Phase 2 trial. Alba Azola discusses Long COVID's challenges, emphasizing the need for awareness and research.

Atea Pharmaceuticals' investigational HCV therapy of bemnifosbuvir and ruzasvir achieved 98% SVR12 after 8 weeks, with 99% success in non-cirrhotic genotypes 1-4 patients and 88% in cirrhotic patients. The company plans to advance to phase 3 in 2025, aiming for a fixed dose combination tablet to enhance patient convenience.

Atea Pharmaceuticals' hepatitis C treatment regimen, combining bemnifosbuvir and ruzasvir, showed 98% sustained virologic response in Phase 2 trial, with 99% success rate among non-cirrhotic patients. The company aims to simplify treatment duration and pill count in Phase 3, targeting a younger, less adherent patient population. Atea seeks to carve a niche in the hepatitis C market with a more convenient treatment option.

Atea Pharmaceuticals' Phase 2 study of bemnifosbuvir and ruzasvir for hepatitis C met primary endpoints with 98% SVR12 rate in adherent patients, demonstrating potency and safety. The Phase 3 program, expected to start in early 2025, will extend treatment duration for cirrhotic patients to 12 weeks.

Atea Pharmaceuticals' Phase 2 study of bemnifosbuvir and ruzasvir for HCV treatment achieved 98% SVR12 with an 8-week regimen, demonstrating safety and efficacy. The company plans to initiate a Phase 3 program in early 2025.

Atea Pharmaceuticals' Phase 2 study for hepatitis C treatment met primary endpoints, showing 98% SVR12 in adherent patients. The regimen, combining bemnifosbuvir and ruzasvir, was safe and well-tolerated. Atea plans to initiate a global Phase 3 program in 2025, aiming to simplify the regimen and enhance patient convenience. The company anticipates contributing to HCV eradication in the U.S. with its treatment.

Atea Pharmaceuticals' Phase 3 SUNRISE-3 study of bemnifosbuvir for Covid-19 treatment did not meet primary goal of reducing hospitalization or death. Bemnifosbuvir is also in Phase 2 for HCV treatment with ruzasvir; additional results planned for Q4.

Atea Pharmaceuticals' Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for COVID-19 did not meet primary endpoint of reducing hospitalization or death. Bemnifosbuvir was safe and well-tolerated. Atea focuses on bemnifosbuvir and ruzasvir combination for hepatitis C treatment.